Skip to main content
. 2022 Jan 11;7(1):e152551. doi: 10.1172/jci.insight.152551

Figure 9. Impact of neonatal GCV treatment on viral load, inflammation, and pyroptosis.

Figure 9

(A) Timeline of GCV treatment. GCV was injected i.p. daily from P1 to P7. Experimental groups included (i) GCV-treated mock-infected (Mock), (ii) PBS-treated MCMV-infected (MCMV, negative treatment control), and (iii) GCV-treated MCMV-infected (MCMV+GCV) mice. (B) GCV treatment and viral loads in brain. Viral genome copy number was assessed by qPCR using DNA extracted from equal amounts of cerebral samples at the indicated time points. Data are from 3 mice/group in 3 independent experiments and analyzed by Student’s t test. (C) GCV treatment and cytokine levels. Levels of IL-1β, IL-18, TNF-α, and IFN-γ in cerebral samples were determined from 6 newborns/group in 3 independent experiments and analyzed by Student’s t test. (D) GCV treatment and immune cells infiltration. Percentages of leukocytes; B, T, and NK cells; neutrophils; monocytes; microglia; and macrophages in total cells of the cerebrum from P7 newborns were assessed by flow cytometry. Data were collected from 12 newborns/group and analyzed by Student’s t test. (E) GCV treatment and pyroptosis. Both full-length and active GSDMD (GSDMD-FL and -N) and IE1 (indicated by arrows) in cerebral lysates were detected by Western blot. GAPDH served as a loading control. For all statistical tests, results are presented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.